Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

EAU 2014, INTERVIEW WITH PROF. DANIEL PETRYLAK

PETRYLAK INTERVIEW

Professor Daniel Petrylak, Head of Prostate and GU Medical Oncology, Director of Prostate Cancer Research Group, Yale Cancer Center Group, New Haven, CT, USA, discusses here a phase 2 trial of prostate specific membrane atigen antibody drug conjugate (PSMA ADC) in taxane-treated metatastic castration resistant prostate cancer (MCRPC).

The content of the videos, articles and all statements expressed therein do not necessarily reflect the opinions or views of the Editors, Authors or Reviewers of European Urology.